BI 1467335 strongly inhibited AOC3 in participants with NASH, with doses ≥3 mg dose-dependently reducing the levels of liver injury biomarkers, ALT and CK-18. Here, KRT18 is linked to metabolic dysfunction-associated steatohepatitis.